Skip to main content
Fig. 6 | Diabetology & Metabolic Syndrome

Fig. 6

From: The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg

Fig. 6

Adapted from Allison et al. [56]

Mean weight loss, categorical weight loss, and percent weight loss by baseline BMI category in the EQUIP trial. Efficacy results are shown with analysis A (prespecified ITT/LOCF). a Mean percent weight loss; b Patients achieving ≥5, ≥10, and ≥15% WL; c LS mean percent weight loss by baseline BMI category. Error bars represent 95% confidence interval. ITT, intent-to-treat; LOCF, last observation carried forward; LS, least-squares; PHEN/TPM CR, controlled-release phentermine/topiramate

Back to article page